ProShares Ultra Health Care (RXL)
| Assets | $70.57M |
| Expense Ratio | 0.95% |
| PE Ratio | 26.59 |
| Shares Out | 1.70M |
| Dividend (ttm) | $0.51 |
| Dividend Yield | 1.17% |
| Ex-Dividend Date | Mar 26, 2025 |
| Payout Ratio | 31.01% |
| 1-Year Return | -6.39% |
| Volume | 2,587 |
| Open | 43.81 |
| Previous Close | 43.65 |
| Day's Range | 42.99 - 43.81 |
| 52-Week Low | 38.39 |
| 52-Week High | 115.04 |
| Beta | 1.43 |
| Holdings | 71 |
| Inception Date | Jan 30, 2007 |
About RXL
Fund Home PageThe ProShares Ultra Health Care (RXL) is an exchange-traded fund that is based on the Health Care Select Sector index. The fund provides 2x leveraged exposure to a cap-weighted index of US health care companies. RXL was launched on Jan 30, 2007 and is issued by ProShares.
Top 10 Holdings
69.31% of assets| Name | Symbol | Weight |
|---|---|---|
| Cte ? Proshares Trust M | n/a | 13.03% |
| United States Treasury Bills 0% | B 0 06.05.25 | 9.58% |
| Eli Lilly and Company | LLY | 8.92% |
| UnitedHealth Group Incorporated | UNH | 8.53% |
| United States Treasury Bills 0% | B 0 05.27.25 | 8.22% |
| Johnson & Johnson | JNJ | 5.65% |
| AbbVie Inc. | ABBV | 4.78% |
| United States Treasury Bills 0% | B 0 06.17.25 | 4.10% |
| Abbott Laboratories | ABT | 3.40% |
| Merck & Co., Inc. | MRK | 3.10% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 26, 2025 | $0.13435 | Apr 1, 2025 |
| Dec 23, 2024 | $0.07359 | Dec 31, 2024 |
| Sep 25, 2024 | $0.1285 | Oct 2, 2024 |
| Jun 26, 2024 | $0.1725 | Jul 3, 2024 |
| Mar 20, 2024 | $0.08603 | Mar 27, 2024 |
| Dec 20, 2023 | $0.08414 | Dec 28, 2023 |
News
ProShares Announces ETF Share Splits
BETHESDA, Md.--(BUSINESS WIRE)--ProShares announced forward and reverse share splits on 22 of its ETFs.
ProShares and ProFunds Announce Benchmark Changes for 53 Geared Sector Funds
BETHESDA, Md.--(BUSINESS WIRE)--ProShares and ProFunds, premier providers of leveraged and inverse funds, announced plans to change the underlying indices for a combined 53 sector ETFs and mutual fu...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
RXL Is The Best Healthcare ETF Wealth-Builder Now
RXL Is The Best Healthcare ETF Wealth-Builder Now